Developing the next generation of CAR-T cell therapies to treat solid cancers

Currus Biologics is utilising its proprietary BEAT technology to develop CAR-T cell therapies that treat solid tumour cancers traditionally difficult to treat with current CAR-T cell therapies.

Currus Biologics’ proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEAT) technology overcomes many of the challenges presented when treating solid tumours with traditional CAR-T cell therapy, demonstrating CAR-T cell proliferation and persistence, CAR-T cell trafficking to the tumour and immunological memory extending to additional antigens.

Currus Biologics is a privately held biotechnology company based in Melbourne, Australia.